Fearful that an election quirk could result in heavily Democratic California installing a Republican as its next governor, a ...

Lauren Yee’s boisterous play “Mother Russia,” about the origins of the contemporary oligarchy, has its roots in her San ...

Coming off a 2024 world premiere in Seattle, Lauren Yee's new comedy skewers both capitalists and communists with equal zeal.

Lookingglass Theatre Company will present the world premiere of White Rooster, written and directed by Ensemble Member Matthew C. Yee (Lucy & Charlie’s Honeymoon). Drawing from a personal family story ...

Re: “Sparks fly at initial debate” (Page A1, Feb. 5). California doesn’t need a governor who “wins” a two-hour TV show. We need a leader who can fix the budget, steady our economy and make government ...

Produced by Damai Entertainment, “Scare Out” represents Zhang’s first venture into modern national security storytelling. The director previously helmed period wuxia epics including “Hero” and “House ...

Progressive outlet The Nation is nominating the city of Minneapolis for the Nobel Peace Prize in the wake of tensions over President Trump’s immigration agenda in the city. In a Wednesday piece, The ...

GammaTime head of production Sandra Yee Ling (Credit: Courtesy of GammaTime) GammaTime, former Miramax executive Bill Block’s microdrama streaming platform aimed at U.S. audiences, has appointed ...

On Tuesday, Stanford Abundance welcomed former California Controller Betty Yee, a candidate in the 2026 gubernatorial election. In a conversation with student host Daniel Stein ’29, speaking to a room ...

From The Breakfast Club to her solo venture Way Up, Angela Yee has built a career on authentic conversation and community. That dedication has translated into four Gracie Awards from the Alliance for ...

Adrian Beaumont does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more. Got a ...